Anti-CD20 in lupus

被引：0
|
作者：
Isenberg, DA [1 ]
Leandro, MJ [1 ]
Ehrenstein, MR [1 ]
Edwards, JCW [1 ]
Manson, J [1 ]
Cambridge, G [1 ]
机构：
[1] Middlesex Hosp, Ctr Rheumatol, London, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：27 / 28
页数：2
相关论文
共 50 条
  • [21] A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus.
    Albert, D
    Khan, S
    Stansberry, J
    Kolasinski, S
    Tsai, D
    Kamoun, M
    Eisenberg, R
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S446 - S447
  • [22] Anti-CD20 therapy for severe and refractory lupus nephritis (RLN).: An original preliminary study
    Abud-Mendoza, C
    Irazoque, F
    Andrade, L
    Cuevas-Orta, E
    Valdés, RV
    Santillán, E
    Navarro-Cano, G
    Saldaña-Barnard, M
    González-Amaro, R
    Borjas, JA
    Aranda, F
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (02) : 427 - 428
  • [23] Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus
    Iwata, S.
    Saito, K.
    Hirata, S.
    Ohkubo, N.
    Nakayamada, S.
    Nakano, K.
    Hanami, K.
    Kubo, S.
    Miyagawa, I.
    Yoshikawa, M.
    Miyazaki, Y.
    Yoshinari, H.
    Tanaka, Y.
    LUPUS, 2018, 27 (05) : 802 - 811
  • [24] Long-term benefits of rituximab (anti-CD20) for refractory systemic lupus erythematosus
    Tanaka, Y.
    Tokunaga, M.
    Nawata, M.
    Suzuki, K.
    Iwata, S.
    Yamaoka, K.
    Nakayamada, S.
    Saito, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 483 - 483
  • [25] A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus.
    Albert, DA
    Khan, SR
    Stansberry, J
    Tsai, D
    Eisenberg, RA
    ARTHRITIS AND RHEUMATISM, 2003, 48 (12): : 3659 - 3659
  • [26] Measuring CD20 binding for humanization of anti-CD20 antibody
    Meng, YJG
    Hong, K
    Presta, L
    Penn, A
    Adams, C
    Chuntharapai, A
    Yang, JH
    Lu, YM
    Wong, WL
    FASEB JOURNAL, 2004, 18 (04) : A59 - A59
  • [27] Rituximab (anti-CD20) zur Behandlung von bullösen AutoimmundermatosenRituximab (anti-CD20) for the treatment of autoimmune bullous diseases
    M. Kasperkiewicz
    D. Zillikens
    Der Hautarzt, 2007, 58 (2): : 115 - 121
  • [28] Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus
    Fukushima, T.
    Dong, L.
    Sakai, T.
    Sawaki, T.
    Miki, M.
    Tanaka, M.
    Masaki, Y.
    Hirose, Y.
    Kuwana, M.
    Umehara, H.
    LUPUS, 2008, 17 (03) : 210 - 214
  • [29] Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus
    ten Cate, R
    Smiers, FJ
    Bredius, RGM
    Lankester, AC
    van Suijlekom-Smit, LWA
    Huizinga, TW
    Egeler, RM
    RHEUMATOLOGY, 2004, 43 (02) : 244 - 245
  • [30] Anti-CD20 monoclonal antibody in autoimmune diseases
    Pogliani, EM
    Larocca, A
    BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 (07) : 350 - 351
12345